{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-033823","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.431994+00:00","generated_at":"2026-06-21T12:33:57.695486+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elite Pharmaceuticals sells rights to generic Sabril (vigabatrin) ANDA to Pyros","bullets":["Sale of rights to approved ANDA for generic Sabril (Vigabatrin Powder for Oral Solution, 500 mg) to Pyros Pharmaceuticals.","Elite executed a three-year manufacturing and supply agreement with Pyros for the product.","Elite will be compensated at an agreed-upon price for manufacturing and packaging.","Agreement executed November 21, 2022; sale has been consummated."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-033823","json":"https://secwatch.observer/filing/0001493152-22-033823.json","markdown":"https://secwatch.observer/filing/0001493152-22-033823.md","text":"https://secwatch.observer/filing/0001493152-22-033823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:33:57.695486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c84d8bfdb8423eb2de767744562b24d767001937","claim":"ELITE PHARMACEUTICALS INC /NV/ entered into Manufacturing and Supply Agreement with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).","evidence_excerpt":"collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Pyros Pharmaceuticals, Inc."},{"label":"Effective","value":"2022-11-21"}],"fact_type":"material_agreement"},{"claim_id":"d1429e670a28bc5671168a12a9c95324056f081a","claim":"ELITE PHARMACEUTICALS INC /NV/ entered into a asset purchase with Pyros Pharmaceuticals, Inc. (effective 2022-11-21).","evidence_excerpt":"On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222033823/0001493152-22-033823-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Pyros Pharmaceuticals, Inc."},{"label":"Effective","value":"2022-11-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}